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clinically compliant protocol. In a porcine model of ischemia and reperfusion injury, intravenous and intracoronary MSC-CM
treatment significantly reduced myocardial nuclear oxidative stress as determined by immunostaining for 8-hydroxy-2′-
deoxyguanosine. In addition, expression levels of phospho-SMAD2 and active caspase 3 were diminished following CM
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Due to limited regenerative capacity of the heart, myocardial
infarction (MI) results in irreversible myocardial cell loss and
functional impairment, eventually leading to heart failure
and death (Lewis et al., 2003). Restoration of antegrade.
Figure 1 Myocardial infarct size. Representative pictures of
Evans blue (blue) and TTC (red) staining on hearts of pigs treated
with (A) non-CM, (B) MSC-CM, or (C) saline. Myocardial infarct
size quantifications as a percentage of the left ventricle (LV) and
the area at risk are shown in (D) and (E), respectively. Non-CM,
n=9; CM, n=9; saline, n=8.
130 L. Timmers et al.coronary perfusion limits myocardial ischemic necrosis and is
the current cornerstone treatment of acute MI (Kleiman
et al., 1994). Despite adequate reperfusion, however, most
patients still suffer irreversible myocardial cell loss. Ironi-
cally, reperfusion itself is an important contributor to
irreversible myocardial tissue loss due to accelerated apop-
tosis, a phenomenon referred to as reperfusion injury
(Saraste et al., 1997). Amelioration of reperfusion injury
and subsequent reduction of myocardial infarct size will
dramatically improve patient prognosis. At present, clinically
effective cardioprotective therapies to reduce reperfusion
injury are still lacking.
Recent developments in stem cell biology have indicated
that stem cells can limit the progression of heart failure and
restore cardiac tissue mass (Smits et al., 2005). In both
experimental and preliminary clinical studies, potential
therapeutic benefits of stem cell transplantation have been
demonstrated (Menasche et al., 2003; Perin et al., 2003;
Shake et al., 2002; Strauer et al., 2002). Among the stem cells
that have been tested for cardiac repair, mesenchymal stem
cells (MSCs) derived fromadult bonemarrow have emerged as
one of the most promising stem cell types for treating
cardiovascular disease (Pittenger and Martin, 2004). The
therapeutic effects of autologous MSCs have been attributed
to their potential to differentiate into many different re-
parative or replacement cell types such as cardiomyocytes,
endothelial cells, and vascular smooth cells (Minguell and
Erices, 2006; Zimmet and Hare, 2005). Because the time
window of opportunity to prevent reperfusion injury after MI
is very short, the use of transplanted MSCs to prevent re-
perfusion injury has received little attention. Recent reports
suggest that some of the therapeutic effects of MSCs are
mediated by paracrine factors secreted by these cells (Caplan
and Dennis, 2006; Gnecchi et al., 2005; Gnecchi et al., 2006).
Potential mechanisms of paracrine MSC actions include
stimulation of endogenous repair, stimulation of angio- and
arteriogenesis, attenuating remodeling, and reducing apop-
tosis. This paracrine hypothesis may extend the repertoire of
stem cell-based therapies with a radically different dimen-
sion, by administration of MSC secretions. If the therapeutic
effects of MSCs are partly mediated by their secretions, such
an approach could potentially provide an “off-the-shelf”
MSC-based therapeutic option, which is a requisite for time-
sensitive protection against reperfusion injury in patients
with acute MI, at affordable costs and with excellent quality
control and consistency.
In this study, we investigate whether secretions of human
MSCs can be employed to reduce myocardial infarct size
following acute MI.
Results and discussion
Human MSC conditioned medium (CM) was generated by
incubation of human embryonic stem cell (hESC)-derived
MSCs in chemically defined culture medium using a clinically
compliant protocol (Lian et al., 2007; Sze et al., 2007). The
medium was concentrated 25 times and sterilized. Thirty
female Dalland Landrace pigs, pretreatedwith clopidogrel for
3 days and amiodarone for 10 days,were randomly assigned to
MSC-CM, non-CM, or saline treatment. Myocardial infarction
was induced by 75 min of proximal left circumflex coronary
artery (LCxCA) ligation, followed by 4 h of reperfusion.Treatment was initiated 5min before the onset of reperfusion
by intravenous infusion of 1.0 ml concentrated MSC-CM, non-
CM, or saline. Immediately following reperfusion, an addi-
tional intracoronary bolus of 4 ml concentrated MSC-CM, non-
CM, or saline was given. The animals were euthanized 4 h
after reperfusion and their hearts were examined.
MSC-CM administration following acute MI reduces
myocardial infarct size
Infarct size, compared to the area at risk (AAR) as well as
compared to the left ventricle (LV), was markedly reduced
in pigs treated with MSC-CM compared to those treated
with non-CM and saline (Fig. 1). MSC-CM treatment resulted
in approximately 60% reduction of infarct size. Importantly,
the AAR was similar in all pigs, which indicates that the
initial ischemic injury did not differ between the groups
(Table 1).
Recently, it has been demonstrated that rat bone marrow
derived MSCs, transduced with the survival gene Akt, can
protect ischemic myocardium via their paracrine secretions
(Gnecchi et al., 2005). Conditioned medium of these Akt-
transformed MSCs appeared cardioprotective, when injected
intramyocardially in a rat model of permanent coronary
artery ligation. A more recent publication revealed that the
cardioprotective effects of the rat Akt-transduced MSCs were
exerted by secreted frizzled-related protein (Sfrp) 2, a pro-
duct specific to Akt-transformed MSCs and not to untrans-
formed MSCs (Mirotsou et al., 2007). Although these data are
intriguing, the observations are built on experimental studies
with limited clinical relevance. First, the secretion was
Table 1 Hemodynamic and functional parameters
Parameter Baseline Myocardial infarction
Non-CM CM Saline Non-CM CM Saline
AAR — — — 35.1±2.9 30.7±1.6 32.4±2.3
IS (% of AAR) — — — 62.2±5.0 25.4±4.8†,‡ 62.5±8.4
IS (% of LV) — — — 22.3±2.9 7.6±1.4†,‡ 20.5±3.1
HR, bpm 83.5±5.5 76.4±5.7 77.6±8.1 111.6±6.3⁎ 86±7.5† 97±5.5
MAP, mm Hg 93.7±10.2 94.0±5.4 100.9±4.9 70.8±9.1⁎ 95.8±4.3‡ 68.5±7.3⁎
QLCx, ml/min 31.9±2.8 28.7±2.9 28.4±4.1 29.9±2.6 25.1±2.6 25.6±3.3
CO, L/min 3.60±0.14 3.25±0.17 3.79±0.23 2.61±0.35⁎ 3.15±0.27‡ 2.04±0.20⁎
WT infarct, cm 0.71±0.04 0.64±0.04 0.71±0.03 1.23±0.09⁎ 0.93±0.09⁎,‡ 1.30±0.09⁎
SWT infarct,% 56.3±5.6 56.9±4.8 61.8±4.3 −6.1±1.4⁎ 18.7±4.1⁎,†,‡ −7.0±1.5⁎
SWT remote, % 43.1±3.3 43.0±3.0 40.9±4.2 43.7±7.4 41.4±6.1 37.8±4.4
FAS, % 42.7±2.9 38.8±2.9 41.3±2.7 24.7±2.6⁎ 36.5±2.0†,‡ 21.7±1.2⁎
EDV, ml 90.3±8.2 86.2±9.1 101.5±7.1 70.2±8.3 69.7±5.2⁎ 69.1±11.6
ESV, ml 47.8±8.2 43.9±6.2 53.0±4.7 44.2±6.0 31.4±1.4⁎ 47.5±9.6
SV, ml 44.5±3.2 43.3±5.0 49.6±3.6 24.5±4.0⁎ 38.5±4.2†,‡ 21.9±2.7⁎
EF, % 52.5±5.0 51.7±3.1 49.0±2.7 38.8±3.5⁎ 54.2±2.6†,‡ 34.7±4.4⁎
dP/dtmax, mm Hg/s 1290±118 1093±83 1299±76 1592±226 1528±130 1075±68⁎
dP/dtmin, mm Hg/s −1614±143 −1329±113 −1650±89 −983± 130⁎ −1031±116⁎ −910±102⁎
Stiffness, mm Hg/ml 0.13±0.03 0.15±0.03 0.14±0.01 0.29±0.06⁎ 0.13±0.01†,‡ 0.29±0.05⁎
Baseline values and myocardial infarction values of pigs treated with non-CM, CM, or saline, determined with echocardiography and
conductance catheter-based LV pressure and volume measurements. AAR, area at risk; IS, infarct size; LV, left ventricle; HR, heart rate;
QLCx, left circumflex coronary artery flow; CO, cardiac output; WT, wall thickness; SWT, systolic wall thickening; FAS, fractional area





131Reduction of myocardial infarct size by human mesenchymal stem cell conditioned mediumprepared from rat bone marrow-derived MSCs that were
retrovirally transduced with the survival gene Akt and there-
fore contained Sfrp2. Second, the conditioned medium was
injected intramyocardially in a rat model of permanent coro-
nary artery ligation. This model has limited clinical relevance
as currently almost all patients undergo reperfusion therapy,
usually by percutaneous coronary intervention. Therefore,
there is a great need for therapeutics that reduce reperfusion
injury rather than ischemic injury.
In contrast to Dai and colleagues, who reported that fresh
culture medium improved LV ejection fraction in a rat model
of MI (Dai et al., 2007), we observed that non-CM did not
protect the myocardium from ischemia and reperfusion in-
jury, as infarct size and function were similar in non-CM- and
saline-treated pigs. The discrepancy between our observa-
tions and the observations of Dai et al. may lie in the differ-
ences in our experimental protocols and the preparation of
the culture medium. We used ischemia/reperfusion in a
model of acute MI versus permanent coronary artery ligation
with a 1-week-old MI. Additionally, our culture medium did
not contain serum, while theirs contained bovine serum. The
presence of serum presents many confounding factors as the
composition of serum is poorly defined and is known to
include growth factors, hormones, and enzymes.
Systolic and diastolic cardiac performance improve
following MSC-CM treatment
In accordance with infarct size reduction, myocardial
systolic and diastolic function improved following MSC-CMtreatment. Baseline parameters were similar in all groups
(Table 1). During ischemia, the posterolateral wall became
completely dyskinetic in all groups, as was observed by
negative values of echocardiographic systolic wall thickening
(SWT; Fig. 2A). Four hours after reperfusion, the reperfused
posterolateral wall of both non-CM and saline control groups
was still dyskinetic. In the pigs treated with MSC-CM,
however, SWT partly recovered (Fig. 2A). Intravenous in-
fusion of the β1-adrenergic receptor agonist dobutamine
further increased systolic wall thickening in the MSC-CM-
treated pigs, whereas no improvement was seen in the con-
trol groups. Usually, myocardial stunning occurs in recently
ischemic myocardium. Stunning refers to sustained func-
tional impairment of viable myocardium following ischemia,
despite restoration of tissue perfusion. Also in this process,
oxidative stress is an important mediator (Bolli et al., 1995).
Stunning is a significant clinical problem, because it con-
tributes to the development of acute heart failure following
myocardial ischemia. Although the functional recovery of
CM-treated cardiac tissues could be attributed to reduced
infarct size, we hypothesize that CM could also alleviate
myocardial stunning through amelioration of oxidative
stress.
Also, global left ventricular systolic function decreased
due to myocardial ischemia (Fig. 2B). In the pigs treated
with CM, the fractional area shortening increased after
reperfusion, almost back to baseline level, and increased
above baseline level during dobutamine infusion. In
control pigs, global systolic function remained impaired.
Improved cardiac function also became evident from the
132 L. Timmers et al.PV-loop-derived indices (Table 1). Left ventricular ejection
fraction and stroke volume were significantly higher in CM-
treated pigs. This translated into improved hemodynamic
parameters such as cardiac output, mean arterial pres-
sure, and heart rate. Diastolic function decreased in con-
trol groups following ischemia and reperfusion injury, as
observed by increased end-diastolic myocardial stiffness.Figure 2 Local and global systolic function. (A) Local systolic
wall thickening as assessed with echocardiography of the infarct
area in pigs treated with non-CM, MSC-CM, or saline. (B) Global
systolic function, measured as echocardiographic fractional area
shortening. Non-CM, n=9; MSC-CM, n=9; saline, n=8.⁎pb0.05
vs non-CM and saline.In the CM-treated pigs, however, diastolic function was not
impaired.
Reduced myocardial oxidative stress and reduced
apoptosis by MSC-CM treatment
Despite using large animal models that are notoriously intrac-
table to mechanistic investigation due to limited research
reagents, we were nonetheless able to identify mechanisms
for CM-elicited cardioprotection against ischemia/reperfusion
injury and subsequent functional recovery. Having demon-
strated the reduction in infarct size and improvement of
function, we first used an in vitro assay of hydrogen peroxide
(H2O2)-induced cell death to determine the effects of CM and
non-CM on oxidative stress, a major cause of ischemia/re-
perfusion injury.We inducedH2O2-mediated oxidative stress in
human leukemic CEM cells in the presence of either CM or non-
CM and monitored cell viability by trypan blue exclusion.
Results showed that CM significantly protected against H2O2-
induced loss of cell viability compared to non-CM (Fig. 3A). To
determine if CM also reduces oxidative stress in the hearts of
CM-treated pigs, nuclear oxidative stress in tissue sections of
pigs treated with CM, non-CM, or saline was quantified by 8-
hydroxy-2′-deoxyguanosine (8-OHdG) immunostaining for oxi-
dizedDNA. Intense nuclear staining indicative of DNAoxidation
was observed in sections of non-CM- and saline-treated pigs
compared with CM-treated pigs (Figs. 3B–D). There were
significantly more positive nuclei in non-CM- and saline-
treated pigs (Fig. 3E). Therefore, CM can confer cytoprotec-
tion against oxidative stress in vitro and in vivo.
The secretions of the MSCs contained many proteins
involved in TGF-β signaling (Sze et al., 2007). To assess
the influence of CM treatment on TGF-β signaling in vivo, we
quantified phosphorylated SMAD2 in the myocardial tissue
samples of CM-treated pigs and control pigs by Western
blotting. CM treatment resulted in reduced pSMAD2 expres-
sion, indicating that TGF-β signaling via ALK-5 was reduced
(Figs. 4A and B). This suggests that altered TGF-β signaling
may be involved in CM-mediated cardioprotection.
Reperfusion injury causes cell death through apoptosis
rather than necrosis (Dumont et al., 2001; Eefting et al.,
2004; Hausenloy and Yellon, 2004).We established that in CM-
treated hearts, apoptotic activity as measured by the level of
activated caspase-3, a central mediator of apoptosis, was
reduced, indicating a CM-associated attenuation of apopto-
sis. In the pigs treated with MSC-CM, active caspase-3 levels
were lower compared to both non-CM control and saline con-
trol, suggesting that CM inhibits myocardial apoptosis
(Figs. 4C and D).
Taking the results together, this study demonstrated that
human MSC-CM protected cardiac tissue from apoptotic cell
death by attenuation of oxidative damage and modulation
of TGF-β signaling. It is not likely that CM protected against
thrombosis in the epicardial coronary artery, since coronary
flow recovered rapidly to normal flow rates after an initial
hyperemic reaction following reperfusion (Table 1). In addi-
tion, all the animals in both test and control groups were
heparinized and treated with clopidogrel to prevent
thrombosis. Furthermore, the CM has no anticoagulative
effect as assayed by activated partial thromboplastin time
and prothrombin time assays (data not shown).
133Reduction of myocardial infarct size by human mesenchymal stem cell conditioned mediumCardioprotection by MSC-CM is mediated by large
complexes
Unfractionated MSC-CM contains products between 10 and
220 nm. In order to come closer to identifying the
cardioprotective factor(s) within the MSC-CM, a b1000-kDa
fraction and a N1000-kDa fraction were generated containing
products ranging in size from 10 to 100 nm and from 100 to
220 nm, respectively. Unfractionated MSC-CM and the
N1000-kDa fraction confer cardioprotection, whereas the
b1000-kDa fraction does not (Fig. 5), indicating that the
cardioprotective factor(s) is in the N1000-kDa fraction with
size ranging from 100 to 220 nm (which is within the size
range of viruses). This means that the active component is a
complex of multiple components that may include proteins
and lipids. Therefore, exact elucidation of the molecular
mechanism for cytoprotection by purifying and identifying
this putative active component is a complex and long-term
undertaking that will be beyond the scope of this article.
Furthermore, medium conditioned by human embryonic
kidney (HEK)-293 cells does not protect the injured
myocardium, which suggests that cardioprotection is cell-
specific. We cannot exclude, however, that such cardiopro-
tective effects can be observed with CM of other stem cells.
Clinical implications
Despite intense efforts, early reperfusion remains the only
therapy to yield improved clinical outcome in patients with
acute MI (Bolli et al., 2004). Translation of promising ex-Figure 3 Oxidative stress. (A) Viability of CEM cells in either CM (n=
medium protects cells from death induced by H2O2. To assess oxida
(B) non-CM, (C) CM, or (D) saline were stained for 8-OHdG, a produ
representative pictures was 400×. (E) Quantification of 8-OHdG-posi
reduces oxidative stress. Non-CM, n=9; CM, n=9; saline, n=8.perimental therapies into clinical applications has been
hampered by the use of experimental designs with limited
clinical relevance. For example, experimental studies in
which cardioprotective treatment is initiated before ische-
mia or during early ischemia have limited clinical relevance
as patients usually suffer acute MI unexpectedly and out of
hospital. To ensure that the efficacy of MSC-CM was assessed
in a clinically relevant manner, we used adult pigs as their
cardiovascular anatomy and physiology are good approxi-
mates of those of humans. The treatment was initiated at a
clinically feasible time point, i.e., during late ischemia and
reperfusion. Although few patients reach the hospital within
75 min after the onset of symptoms, we deliberately chose
75 min of ischemia because it induces a pathological
substrate comparable to that of the average patient with
acute MI. In pig, unlike human, ischemic periods of N2 h
followed by reperfusion will result in completely transmural
myocardial infarctions. Such large transmural infarctions are
rarely observed in patients, even if the intervention takes
place several hours after the onset of symptoms. Factors such
as the presence of collateral arteries, ischemic precondition-
ing, and residual flow may delay cardiomyocyte death in
patients and account for the difference between pig and
human. We selected clinically relevant end points, such as
myocardial infarct size and cardiac function, which will
facilitate translation of the outcomes of this experimental
study to a clinical setting. However, therapeutic efficacy and
safety of human MSC-CM remain to be validated in clinical
practice. Although the significantly reduced tissue loss and
the substantial functional recovery following CM therapy
strongly point to sustained protection, long-term follow-up of4) or non-CM (n=4) and treatedwith H2O2 (⁎pb0.05). Conditioned
tive stress in vivo, infarct area sections from pigs treated with
ct of nuclear oxidative stress. The original magnification of the
tive nuclei was assessed at 200× magnification. Also in vivo, CM
Figure 4 TGF-β signaling and apoptosis. Western blot for (A, B) phosphorylated SMAD2 and (C, D) active caspase 3 in pigs treatedwith
non-CM, CM, or saline. (E) β-Tubulin was assessed as a loading control, and no differences were found in β-tubulin expression between
the groups. Non-CM, n=9; CM, n=9; saline, n=8.
134 L. Timmers et al.CM therapy is essential to exclude a delay in, rather than
prevention of, cardiac injury. Cardiovascular risk factors such
as age, hypertension, dyslipidemia, and diabetes may
influence the outcome of MI and are potential confounding
factors that will have to be evaluated. Other potential
confounding factors include collateralization in patients with
chronic stenotic coronary arteries, residual coronary flow
during ischemia, and ischemic preconditioning.
This study demonstrates that human MSC-CM exerts
significant cardioprotective effects and substantially pre-
serves cardiac function in a pig model of myocardial ischemia
and reperfusion injury. It elicits this protection through
reduced apoptotic activity that possibly results from CM-
associated attenuation of oxidative stress and altered TGF-β
signaling.Most importantly, this study usedCMof humanorigin
in a clinically relevant large animal model with assessment of
clinically relevant end points and therefore engenders direct
and immediate clinical implications. This study could poten-
tially extend the repertoire of stem cell-based therapy, as the
data suggest that secretions of stem cells could be used in
place of cells in some clinical applications and circumvent
complications associated with cell-based therapy such asimmunocompatibility, tumorigenicity, ethics, costs, and wait-
ing time for ex vivo expansion.
Methods
MSC-CM preparation
The protocols for MSC generation and CM preparation have
been described previously (Lian et al., 2007; Sze et al.,
2007). In short, a chemically defined serum-free culture
medium was conditioned by MSCs derived from hESC's, using
a clinically compliant protocol. Three polyclonal, karyotypi-
cally stable, and phenotypically MSC-like cultures, that did
not express pluripotency-associated markers but displayed
MSC-like surface antigens (CD29+, CD44+, CD49a+/e+,
CD105+, CD166+, CD34−, CD45−) and gene expression profile,
were generated by trypsinization and propagation of hESC's
from either the HuES9 hESC line or the H1 hESC line in
feeder- and serum-free selection medium (Lian et al., 2007).
One of these cultures, HuES9.E1, can be stably expanded for
at least 80 population doublings. To harvest MSC secretions,
HuES9.E1 cultures were transferred to a chemically defined,
Figure 5 Cardioprotective properties of CM fractions. Myo-
cardial infarct size quantification in mice treated with saline
(n=10), unfractionatedMSC-CM (n=12), HEK-293-CM (n=10), the
b1000-kDa fraction (n=8), and the N1000-kDa fraction (n=8).
Unfractionated MSC-CM reduces myocardial infarct size com-
pared to saline-treated animals, in contrast to HEK-293-CM. The
N1000-kDa fraction of MSC-CM reduces infarct size, whereas the
b1000-kDa fraction does not, indicating that the cardioprotec-
tive factor(s) is larger than 1000 kDa. ⁎pb0.05 vs saline.
135Reduction of myocardial infarct size by human mesenchymal stem cell conditioned mediumserum-free culture medium to condition the medium for
3 days before the media containing MSC secretions were
collected, clarified by centrifugation, concentrated 25 times
using 10-kDa MW cutoff ultrafiltration membranes, and
sterilized by filtration through a 220-nm filter. The secretory
proteome was analyzed by multidimensional protein identi-
fication technology and cytokine antibody array analysis and
revealed the presence of 201 unique gene products.
Computational analyses disclosed that this CM holds poten-
tial cytoprotective properties (Sze et al., 2007).
Animals
All experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Pigs prepared by
the Institute of Laboratory Animal Resources and with prior
approval by the Animal Experimentation Committee of the
Faculty of Medicine, Utrecht University, the Netherlands.
Study design
Thirty female Dalland Landrace pigs (60–70 kg; IDDLO,
Lelystad, The Netherlands), all pretreated with clopidogrel
75 mg/day for 3 days and amiodarone 400 mg/day for
10 days, were randomly assigned to MSC-CM, non-CM, or
saline treatment. The saline group was added to assess a
potential effect of fresh, nonconditioned culture medium. In
all pigs, MI was induced by 75 min of proximal LCxCA ligation
and 4 h of subsequent reperfusion. An ischemic period of
75 min was selected to inflict severe myocardial injury
without inducing completely transmural myocardial infarc-
tion. The 4-h reperfusion period was used because infarct
size measurement using triphenyltetrazolium chloride (TTC)
staining is most reliable after 3 h of reperfusion (Birnbaumet al., 1997). After longer periods of reperfusion, it becomes
more difficult to assess oxidative stress status and apoptotic
mechanisms. Treatment was initiated 5 min before the onset
of reperfusion by intravenous infusion of MSC-CM (1.0 ml,
2.0 mg protein), non-CM, or saline. Immediately following
reperfusion, an additional intracoronary bolus of MSC-CM
(4.0 ml, 8.0 mg protein), non-CM, or saline was given.
MI and operational procedure
During the entire operation, ECG, systemic arterial pressure,
and capnogram were monitored continuously. Under general
anesthesia as described before (Timmers et al., 2007a), a
median sternotomy was performed and two introduction
sheets were inserted in the carotid arteries for a 6-Fr guiding
catheter and an 8-Fr conductance catheter (CD Leycom,
Zoetermeer, the Netherlands). The distal tip of a Swan Ganz
catheter was placed into the pulmonary artery via the
internal jugular vein. Transonic flow probes (Transonic
Systems, Ithaca, NY, USA) were placed around the proximal
aorta and LCxCA to measure cardiac output and coronary
flow, and a wire was placed around the inferior caval vein to
enable functional measurements under varying loading
conditions for PV loops. After functional measurements,
10,000 IU of heparin was administered intravenously and
sutures were tightened to occlude the proximal LCxCA.
Internal defibrillation with 50 J was used when ventricular
fibrillation occurred. After 75min of ischemia, the LCxCAwas
reopened by release of the suture. Immediately following
reperfusion, nitroglycerine (0.1mg to prevent no-reflow)was
infused through the LCxCA via the guiding catheter, followed
by intracoronary treatment with MSC-CM, non-CM, or saline.
After 4 h of reperfusion, the final functional measurements
were performed and the heart was explanted for infarct size
analysis.
Functional measurementsShort axis epicardial ultrasound and LV pressure and volume
were measured using the conductance catheter method, as
described previously (Timmers et al., 2007b). LV pressure
and volume signals derived from the conductance catheter
were displayed and acquired at a 250-Hz sampling rate with a
Leycom CFL-512 (CD Leycom). Data were acquired during
steady state and during temporal caval vein occlusion, all
with the ventilator turned off at end expiration. Analysis of
the pressure–volume loops was performed with custom
software as described previously (Steendijk et al., 1998). In
addition, short-axis epicardial ultrasound images (Prosound
SSD-5000, 5-MHz probe UST-5280-5; Aloka Holding Europe
AG, Zug, Switzerland) were obtained at the midpapillary
muscle level. Wall thickness (WT) of the infarct area, remote
area (septum), and LV internal area (LVia) were measured at
end diastole (ED) and end systole (ES). SWTwas calculated as
[(WT(ES) − WT(ED))/WT(ED)]×100%, fractional area short-
ening as [(LVia(ED) − LVia(ES))/LVia(ED)]×100%, and left
ventricular ejection fraction as [(EDV − ESV)/EDV]×100%.
The end-diastolic chamber stiffness was quantified by means
of linear regression of the end-diastolic pressure–volume
relationship. Echocardiography and PV loops were measured
before MI, 1 h after ischemia, and 4 h after reperfusion. To
136 L. Timmers et al.challenge stunned myocardium, additional measurements
were performed during pharmaceutically induced stress
by intravenous dobutamine infusion (2.5 μg/kg/min and
5.0 μg/kg/min).
Infarct size
Just prior to excision of the heart, the LCxCA (pigs) or left
coronary artery (LCA) (mice) was religated at exactly the
same spot as for the induction of the MI. Evans blue dye was
infused through the coronary system to delineate the AAR.
The heart was then excised, and the LV was isolated and cut
into five slices from apex to base. The slices were incubated in
1% TTC (Sigma–Aldrich Chemicals, Zwijndrecht, the Nether-
lands) in 37 °C Sörensen buffer (13.6 g/L KH2PO4 + 17.8 g/L
Na2H PO4 · 2H2O, pH 7.4) for 15 min to discriminate infarct
tissue from viable myocardium. All slices were scanned from
both sides, and in each slide, the infarct area was compared
with area at risk and the total area by use of digital planimetry
software (ImageJ). After correction for the weight of the
slices, infarct size was calculated as a percentage of the AAR
and of the LV.
Oxidation-induced cell death assay
Human leukemic CEM cells were plated in six-well plates and
incubated in either CM (unconcentrated, i.e., 80 μg/ml
protein) or non-CM and treated with 50 μM H2O2 to induce
oxidative stress. Cell viability was assessed using trypan blue
exclusion at 12, 24, 36, and 48 h after H2O2 treatment.
Immunohistochemistry
Nuclear oxidative stress in the ischemia and reperfusion area
was assessed by immunostaining for 8-OHdG, a product of
oxidative stress to DNA. Tissue samples were fixed in 4%
formalin before being embedded in paraffin. Following
antigen retrieval in 10 mM citric acid, the tissue sections
were incubated with 10% normal horse serum for 30 min,
mouse anti-8-OHdG (OXIS International, Foster City, CA, USA)
1:20 in 0.1% PBSA overnight at 4 °C, biotin-labeled horse anti-
mouse (Vector Laboratories, Burlingame, CA, USA) 1:500 for
1 h, and streptavidin–HRP 1:1000 for 1 h. Finally, the sections
were incubated with H2O2–diaminobenzidine for 10 min. The
amount of 8-OHdG-positive nuclei was quantified in four
randomly picked fields per section with the digital image
microscopy software Analysis (Olympus, Münster, Germany)
at 200× magnification.
Western blotting
Protein was isolated from frozen tissue samples collected
from the ischemia/reperfusion area of pigs using 1 ml Tripure
Isolation Reagent (Boehringer, Mannheim, Germany) accord-
ing to the manufacturer's protocol. Eight micrograms of total
protein was separated on by 10% SDS–PAGE, transferred onto
a Nitrocellulose C membrane (Amersham, Buckinghamshire,
UK), and blocked using phosphate-buffered saline–0.1%
Tween–5% Protifar (Nutricia, Netherlands). The membrane
was incubated with a rabbit antibody for phospho-SMAD2
1:1000 (Cell Signaling Technology), for active caspase-3 1:100(Chemicon, Germany), or for β-tubulin 1:5000 (Abcam,
Cambridge, UK) and subsequently with goat anti-rabbit HRP
1:2000 (DAKO, Glostrup, Denmark). Chemiluminescence
substrate (NENk Life Science Products) was used for detec-
tion; the bands were analyzed using the Gel Doc 1000 system
(Bio-Rad, Veenendaal, Netherlands).
MSC-CM fractionation
The MSC-CM was prepared by sterile filtration through a 220-
nm filter and concentrated through a 10-nm filter and
therefore contains components between 10 and 220 nm. Sub-
sequently, a b1000-kDa fraction and a N1000-kDa fraction
were prepared by filtering the MSC-CM through a 1000-kDa-MW
cutoff membrane with a 100-nm nominal pore size (Pall Corp.,
Singapore), generating a fraction containing products between
10 and 100 nm and a fraction containing products between 100
and 220 nm. To identify the fraction containing the factor(s)
within the medium that confers cardioprotection (10–100 or
100–220 nm), a mouse model of ischemia and reperfusion
injury was used. MI was induced by 30 min LCA occlusion and
subsequent reperfusion. Mice were treated with 20 μl unfrac-
tionated MSC-CM (10–220 nm), b1000-kDa fraction (10–
100 nm), N1000-kDa fraction, or saline intravenously via the
tail vein, 5 min before reperfusion. Infarct size was assessed
24 h later using Evans blue and TTC as described previously
(Timmers et al., 2007a). An additional group of mice was
examined with medium conditioned by HEK-293 cells, to
investigate whether the cardioprotective effect is cell-
specific.
Data analysis
Data are presented as means ± SEM. Values were collected in
a blinded fashion and compared using one-way ANOVA with
post hoc Bonferroni tests in SPSS 15.0. Cardioprotective
potential of the human MSC-CM fractions was compared to
saline using a one-way ANOVAwith Dunnett's post hoc tests. A
p value of b0.05 was considered significant.
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